Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 41Carcinoma, Non-Small-Cell Lung 35Carcinoma, Renal Cell 26Neoplasm Metastasis 19Lung Neoplasms 18Carcinoma, Hepatocellular 15Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Pancreatic Neoplasms 10Neoplasms 9Carcinoma, Transitional Cell 9Multiple Myeloma 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Head and Neck Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Hodgkin Disease 6Advanced Cancer 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Skin Neoplasms 4Recurrence 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Uveal Melanoma 3

Interventions

enzalutamide 4abiraterone 2Docetaxel 2tasquinimod 1sabizabulin 1olaparib 1ipatasertib 1darolutamide 1atezolizumab 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms, Castration-Resistant × Nivolumab × Clear all
NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 2 Terminated
10 enrolled 15 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡